公开(公告)号：US08841264B2

公开(公告)日：2014-09-23

申请号：US12373584

申请日：2007-07-12

Applicant: Daniel Raederstorff ,  Nathalie Richard ,  Joseph Schwager ,  Karin Wertz

Inventor： Daniel Raederstorff ,  Nathalie Richard ,  Joseph Schwager ,  Karin Wertz

IPC: A01N43/04 ,  A61K31/70 ,  A01N43/16 ,  A61K31/35 ,  A01N31/08 ,  A61K31/05 ,  A01N31/00 ,  A61K31/045 ,  A01N29/00 ,  A61K31/01 ,  C07H13/02 ,  A61K31/343 ,  A61K31/366

CPC classification number: A61K31/343 ,  A61K31/05 ,  A61K31/366 ,  A61K2300/00

Abstract: Compositions containing a combination of hydroxytyrosol and resveratrol or liqustilide or (−)-epigallocatechin gallate or honokiol or genistein or Magnolia bark extract or a combination of oleuropein and resveratrol or ligustilide are used to treat inflammatory disorders.

Abstract translation: 含有羟基酪醇和白藜芦醇或苯磺酰肼或（ - ） - 表没食子儿茶素没食子酸酯或和厚朴酚或染料木素或木兰树皮提取物或橄榄苦蛋白和白藜芦醇或琉璃酰苯的组合的组合物用于治疗炎症性疾病。

公开(公告)号：US20120225840A1

公开(公告)日：2012-09-06

申请号：US13264819

申请日：2009-10-15

Applicant: Ann Fowler ,  Angelika Friedel ,  Darko Knutti ,  Karin Kuratli ,  Daniel Raederstorff ,  Ying Wang-Schmidt ,  Karin Wertz

Inventor： Ann Fowler ,  Angelika Friedel ,  Darko Knutti ,  Karin Kuratli ,  Daniel Raederstorff ,  Ying Wang-Schmidt ,  Karin Wertz

IPC: A61K31/714 ,  A61P3/02 ,  A61K31/522 ,  A61P21/00 ,  A61K31/045 ,  A61K31/352

CPC classification number: A61K31/05 ,  A23K20/111 ,  A23K20/121 ,  A23K20/147 ,  A23K20/174 ,  A23L2/52 ,  A23L33/10 ,  A23L33/105 ,  A23L33/11 ,  A23L33/15 ,  A23L33/175 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/122 ,  A61K31/145 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/205 ,  A61K31/34 ,  A61K31/352 ,  A61K31/4188 ,  A61K31/4406 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/522 ,  A61K31/525 ,  A61K31/714 ,  A61K36/63 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/33 ,  A23V2250/2108 ,  A23V2250/7042 ,  A23V2250/7044 ,  A23V2250/7046 ,  A23V2250/705 ,  A23V2250/706 ,  A23V2250/72

Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.

Abstract translation: 含有羟基酪醇的羟基酪醇或橄榄油与选自肌酸，辅酶Q10，白藜芦醇，咖啡因，肉碱，B族维生素（B1，B2，B3，B5，B6和/或B12）中的至少一种化合物组合 ）和人参（优选：根）提取物可用于维持或增加心肌，骨骼肌和肝组织中的线粒体生物发生。

公开(公告)号：US08158681B2

公开(公告)日：2012-04-17

申请号：US12279510

申请日：2007-02-13

Applicant: Daniel Raederstorff ,  Joseph Schwager ,  Goede Schueler

Inventor： Daniel Raederstorff ,  Joseph Schwager ,  Goede Schueler

IPC: A61K31/20 ,  A61K31/085 ,  A61K31/192 ,  A61P19/02 ,  C07C43/23 ,  C07C65/28

CPC classification number: C07C43/23 ,  C07C65/28 ,  C07D311/58

Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract translation: 本发明涉及新的甲氧基化芳族化合物。 它还涉及包含甲氧基化芳族化合物的新型组合物以及这些组合物作为药物，特别是作为治疗，共同治疗或预防炎症性疾病的药物的用途。

公开(公告)号：US20100113612A1

公开(公告)日：2010-05-06

申请号：US12596481

申请日：2008-04-17

Applicant: Daniel Raederstorff ,  Ying Wang-Schmidt ,  Karin Wertz

Inventor： Daniel Raederstorff ,  Ying Wang-Schmidt ,  Karin Wertz

IPC: A61K31/05 ,  A61P39/06

CPC classification number: A61K36/63 ,  A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  A23V2250/2131 ,  A61K31/05 ,  A61K31/7048 ,  A23V2200/302 ,  A23V2250/2132 ,  A23V2250/708 ,  A23V2250/032 ,  A23V2250/5072 ,  A23V2250/211

Abstract: The present invention is directed to the use of (a composition comprising) hydroxytyrosol as life prolonging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is preferably administered orally to animals. The present invention is further directed to a life prolonging method. “Life prolonging” meaning in the context of the present invention: reducing the risk to die at a certain age compared to untreated; increasing the chance to live longer (longevity), i.e. increasing the average life expectancy compared to untreated; and/or extending the lifetime independent of medical care.

Abstract translation: 本发明涉及（含有羟基酪醇的组合物）作为延长剂的用途。 本发明也涉及的组合物基本上不包含白藜芦醇，并且优选口服给予动物。 本发明还涉及寿命延长方法。 本发明背景下的“延续寿命”意义：降低与未经治疗相比在一定年龄死亡的风险; 增加延长寿命（延长寿命）的机会，即增加与未治疗相比的平均预期寿命; 和/或延长终身独立于医疗保健的寿命。

公开(公告)号：US20100113584A1

公开(公告)日：2010-05-06

申请号：US12524207

申请日：2008-01-17

Applicant: Daniel Raederstorff ,  Anna-Maria Stiefel ,  Swen Wolfram

Inventor： Daniel Raederstorff ,  Anna-Maria Stiefel ,  Swen Wolfram

IPC: A61K31/352 ,  C07D311/62 ,  A61P43/00

CPC classification number: A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  A23V2250/032 ,  A23V2250/6422 ,  A23V2250/51082 ,  A23V2250/708 ,  A23V2250/214 ,  A23V2250/2132

Abstract: Use of (−)-epigallocatechin gallate and/or one or more of its derivatives for increasing the desire, willingness and/or motivation of animals (including humans), especially mammals, to exercise, to perform and/or to run, especially to perform endurance exercise and furthermore to accelerate training success.

Abstract translation: （ - ） - 表没食子儿茶素没食子酸酯和/或其一种或多种衍生物用于增加动物（包括人类）特别是哺乳动物的运动，执行和/或运行的愿望，意愿和/或动机，尤其是 进行耐力运动，进一步加快训练成功。

公开(公告)号：US20100093843A1

公开(公告)日：2010-04-15

申请号：US12438405

申请日：2007-09-12

Applicant: Joseph Schwager ,  Daniel Raederstorff ,  Goede Schueler

Inventor： Joseph Schwager ,  Daniel Raederstorff ,  Goede Schueler

IPC: A61K31/352 ,  C07D311/86 ,  A61P19/00

CPC classification number: A61K31/352

Abstract: The invention relates to novel nutraceutical and pharmaceutical compositions comprising at least a compound of the general formula (I), wherein R1 and R2 are independently from each other C1-8-alk(en)yl and R3 and R4 are independently from each other hydroxy or C1-8-alkyloxy, as well as to the use of these compositions for the treatment, co-treatment or prevention of joint disorders.

Abstract translation: 本发明涉及至少包含通式（I）化合物的新型营养药物和药物组合物，其中R1和R2彼此独立地为C1-8-烷（烯）基，R3和R4彼此独立为羟基 或C 1-8烷氧基，以及这些组合物用于治疗，共同治疗或预防关节疾病的用途。

公开(公告)号：US20100055218A1

公开(公告)日：2010-03-04

申请号：US12373617

申请日：2007-07-12

Applicant: Daniel Raederstorff ,  Joseph Schwager ,  Karin Wertz

Inventor： Daniel Raederstorff ,  Joseph Schwager ,  Karin Wertz

IPC: A61K36/73

CPC classification number: A61K36/484 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/635 ,  A61K36/185 ,  A61K36/23 ,  A61K36/575 ,  A61K36/738 ,  A61K36/76 ,  A61K36/77 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/324 ,  A23V2250/21

Abstract: The present invention relates to novel compositions comprising rosehip and at least one additional component e.g. selected from ligustilide, oleuropein (I), oleuropein aglycone (II), hydroxytyrosol, genistein, magnolol, honokiol, magnolia bark extract, cashew fruit extract and Glycyrrhiza foetida as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract translation: 本发明涉及包含玫瑰果和至少一种另外的组分的新型组合物，例如 选自ligustilide，oleuropein（I），oleuropein糖苷配基（II），羟基酪醇，染料木素，厚朴酚，厚朴酚，木兰树皮提取物，腰果提取物和甘草，以及这些组合物作为药物的用途，特别是作为 用于治疗，共同治疗或预防炎症性疾病的药物。

公开(公告)号：US20090163579A1

公开(公告)日：2009-06-25

申请号：US11990395

申请日：2006-10-11

Applicant: Daniel Raederstorff ,  Ying Wang-Schmidt ,  Swen Wolfram

Inventor： Daniel Raederstorff ,  Ying Wang-Schmidt ,  Swen Wolfram

IPC: A61K31/353 ,  A61K31/05 ,  A61P21/00

CPC classification number: A61K31/05 ,  A61K31/353

Abstract: The use of at least one component selected from the group consisting of EGCG, hydroxytyrosol, resveratrol and derivatives, metabolites or analogues thereof in the manufacture of a nutraceutical composition for the prevention and treatment of muscle wasting leading to muscle loss, atrophy and other associated muscle disorders in animals, in particular mammals including humans.

Abstract translation: 使用至少一种选自EGCG，羟基酪醇，白藜芦醇及其衍生物，代谢物或类似物的组分在制备营养组合物中用于预防和治疗导致肌肉损失的肌肉消瘦，萎缩和其它相关肌肉 动物，特别是哺乳动物，包括人类的疾病。

公开(公告)号：US20150030579A1

公开(公告)日：2015-01-29

申请号：US14450073

申请日：2014-08-01

Applicant: Ann FOWLER ,  Angelika FRIEDEL ,  Darko KNUTTI ,  Karin KURATLI ,  Daniel RAEDERSTORFF ,  Ying WANG-SCHMIDT ,  Karin WERTZ

Inventor： Ann FOWLER ,  Angelika FRIEDEL ,  Darko KNUTTI ,  Karin KURATLI ,  Daniel RAEDERSTORFF ,  Ying WANG-SCHMIDT ,  Karin WERTZ

IPC: A61K31/05 ,  A61K36/63 ,  A61K31/522 ,  A61K31/195 ,  A61K31/19 ,  A61K31/51 ,  A61K31/145 ,  A61K31/34 ,  A61K31/352 ,  A61K31/4188 ,  A61K31/525 ,  A61K31/4406 ,  A61K31/714 ,  A23L1/30 ,  A61K31/122

CPC classification number: A61K31/05 ,  A23K20/111 ,  A23K20/121 ,  A23K20/147 ,  A23K20/174 ,  A23L2/52 ,  A23L33/10 ,  A23L33/105 ,  A23L33/11 ,  A23L33/15 ,  A23L33/175 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/122 ,  A61K31/145 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/205 ,  A61K31/34 ,  A61K31/352 ,  A61K31/4188 ,  A61K31/4406 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/522 ,  A61K31/525 ,  A61K31/714 ,  A61K36/63 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/33 ,  A23V2250/2108 ,  A23V2250/7042 ,  A23V2250/7044 ,  A23V2250/7046 ,  A23V2250/705 ,  A23V2250/706 ,  A23V2250/72

Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.

Abstract translation: 含有羟基酪醇的羟基酪醇或橄榄油与选自肌酸，辅酶Q10，白藜芦醇，咖啡因，肉碱，B族维生素（B1，B2，B3，B5，B6和/或B12）中的至少一种化合物组合 ）和人参（优选：根）提取物。 可用于维持或增加心肌，骨骼肌和肝组织中的线粒体生物发生。

公开(公告)号：US20110300240A1

公开(公告)日：2011-12-08

申请号：US13202154

申请日：2010-02-19

Applicant: Daniel Raederstorff ,  Nathalie Richard ,  Joseph Schwager ,  Christof Wehrli ,  Swen Wolfram

Inventor： Daniel Raederstorff ,  Nathalie Richard ,  Joseph Schwager ,  Christof Wehrli ,  Swen Wolfram

IPC: A61K36/00 ,  A61P19/02 ,  A61Q19/00 ,  A61P25/00 ,  A61K8/97 ,  A61P29/00 ,  A61P3/10

CPC classification number: A61K31/7008 ,  A61K36/48 ,  A61K2300/00

Abstract: The present invention relates to novel compositions comprising Cajanus and glucosamine as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract translation: 本发明涉及包含Cajanus和葡糖胺的新型组合物以及这些组合物作为药物，特别是作为治疗，共同治疗或预防炎症性疾病的药物的用途。